Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
The proteasome has emerged as a novel target for antineoplastic treatment of hematological malignancies and solid tumors, including those of the central nervous system. To identify cell death pathways activated in response to inhibition of the proteasome system in cancer cells, we treated human SH-SY5Y neuroblastoma cells with the selective proteasome inhibitor (PI) epoxomicin (Epoxo). Prolonged exposure to Epoxo was associated with increased levels of poly-ubiquitinylated proteins and p53, release of cytochrome c from the mitochondria, and activation of caspases. Analysis of global gene expression using high-density oligonucleotide microarrays revealed that Epoxo triggered transcriptional activation of the two Bcl-2-homology domain-3-only (BH3-only) genes p53 upregulated modulator of apoptosis (PUMA) and Bim. Subsequent studies in PUMA- and Bim-deficient cells indicated that Epoxo-induced caspase activation and apoptosis was predominantly PUMA-dependent. Further characterization of the transcriptional response to Epoxo in HCT116 human colon cancer cells demonstrated that PUMA induction was p53-dependent; with deficiency in either p53 or PUMA significantly protected HCT116 cells against Epoxo-induced apoptosis. Our data suggest that p53 activation and the transcriptional induction of its target gene PUMA play an important role in the sensitivity of cancer cells to apoptosis induced by proteasome inhibition, and imply that antineoplastic therapies with PIs might be especially useful in cancers with functional p53.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As proteasome inhibitors induce apoptosis in several cell lines [26–28]”
From PSMC5 insufficiency and P320R mutation impair proteasome function (2024) · cites this paper as [27]
Citations
Cites
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 1×
“NF-kB is constitutively activated in many cancer cells and is associated with cancer development and progression (Karin, 2006).”
BackgroundA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“Indeed, clinical efficiency of Bortezomib (PS-341/Velcade), a reversible PI has recently been observed in multiple myeloma patients (Richardson et al., 2003).”
BackgroundPUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315 · cited 2×
“PUMA has been identified as a key mediator of the p53dependent apoptotic response (Nakano and Vousden, 2001; Yu et al., 2001).”
BackgroundPalombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096 · cited 1×
“Indeed, the activity of several transcription factors, including p53 and nuclear factor kappa B (NF-kB) (Chowdary et al., 1994; Palombella et al., 1994), are known to be modulated by proteasome activity.”
Backgroundc-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715 · cited 1×
“The most prominently downregulated genes after proteasome inhibition were members of the c-Myc family of transcription factors which control expression of genes involved in cell growth and metabolism (Dang, 1999).”
BackgroundBouillet, P., Metcalf, D., Huang, D. C. S., Tarlinton, D. M., Kay, T. W. H., Köntgen, F., Adams, J. M., & Strasser, A. (1999) · Science · doi:10.1126/science.286.5445.1735 · Cited by 1,504 · cited 1×
“The generation of the PUMA / and Bim / mice have been described previously (Bouillet et al., 1999; Villunger et al., 2003a).”
MethodSelf-citationp53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327 · cited 3×
“Oncogene imbalance between proapoptotic and antiapoptotic Bcl-2 proteins resulting in the release of cytochrome c and apoptosis (Villunger et al., 2003a; Willis and Adams, 2005).”
BackgroundMethodSelf-citationPUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells
Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., & Vogelstein, B. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00213-1 · Cited by 1,280 · cited 3×
“PUMA has been identified as a key mediator of the p53dependent apoptotic response (Nakano and Vousden, 2001; Yu et al., 2001).”
BackgroundThe proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201 · cited 1×
“Several key regulatory proteins involved in cell proliferation and differentiation are regulated by proteasome-mediated proteolysis resulting in the activation or inhibition of specific cell signaling pathways (”
BackgroundKuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185 · cited 2×
“…a recent study suggesting that a Bim BH3 peptide may be a more potent inducer of cytochrome c release and apoptosis than its PUMA counterpart (Kuwana et al., 2005), suggesting that potency of BH3-only proteins may also be dependent on functional interactions with other molecules within the…”
BackgroundKILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083 · cited 2×
“…mediates cell death largely through PUMA induction, and that other transcriptional, proapoptotic targets of p53 such as Fas (Owen-Schaub et al., 1995) and Trail-R2 (Wu et al., 1997) may play a less pronounced role, although they may additionally sensitize cells to therapies involving death ligands.”
BackgroundEpoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
Meng, L., Mohan, R., Kwok, B. H. B., Elofsson, M., Sin, N., & Crews, C. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10403 · Cited by 920 · cited 3×
“Unlike several widely used PIs, Epoxo is highly specific for the proteasome without affecting the activity of other non-proteasomal proteases including calpain, trypsin and cathepsin B (Meng et al., 1999).”
BackgroundInfluentialNF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893 · cited 2×
“Indeed, inactivation of NF- κ B has been suggested to play a major role in the antitumor effect of the PI, Bortezomib (VelcadesPS-341), in multiple myeloma (”
BackgroundIKK/NF- B signaling: balancing life and death - a new approach to cancer therapy
Luo, J.-L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26322 · Cited by 878 · cited 4×
“NF- κ B potently inhibits apoptosis by activation of antiapoptotic target genes such as Bcl-xL and IAPs ) (”
BackgroundInfluentialLife in the balance: how BH3-only proteins induce apoptosis
Willis, S. N., & Adams, J. M. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.10.001 · Cited by 743 · cited 2×
“Oncogene imbalance between proapoptotic and antiapoptotic Bcl-2 proteins resulting in the release of cytochrome c and apoptosis (Villunger et al., 2003a; Willis and Adams, 2005).”
BackgroundMolecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741 · cited 13×
“Proteasome inhibitors (PIs) have been demonstrated to overcome chemoresistance of tumor cells by enhancing chemosensitivity and even acting in synergy with other agents to induce apoptotic cell death of tumor cells (Adams, 2002; Park and Lenz, 2004).”
ResultInfluentialWild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression
Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W.-W., Kruzel, E., et al. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3032 · Cited by 734 · cited 4×
“Amongst those identified in this group included the death receptors Fas/ Apo1 and TRAIL-R2 as well as several members of the Bcl-2 family of proteins including the BH3-only members, Bim and PUMA.”
BackgroundInfluentialSuzuki, Y., Nakabayashi, Y., & Takahashi, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161506698 · Cited by 654 · cited 1×
“An endogenous caspase inhibitor family of proteins, the inhibitor of apoptosis (IAPs), not only inhibit active caspases but also target them for destruction by acting as ubiquitin ligases and promoting polyubiquitination of activate caspases (Huang et al., 2000; Suzuki et al., 2001).”
BackgroundLey, R., Balmanno, K., Hadfield, K., Weston, C., & Cook, S. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301010200 · Cited by 608 · cited 2×
“This apparent discrepancy is likely caused by a decreased turnover of the BimEL protein after inhibition of the proteasome (Figure 3b, right panel), as BimEL has previously been shown to be targeted for degradation by the ubiquitin-proteasome pathway (Ley et al., 2003).”
BackgroundPUMA mediates the apoptotic response to p53 in colorectal cancer cells
Yu, J., Wang, Z., Kinzler, K. W., Vogelstein, B., & Zhang, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2627984100 · Cited by 563 · cited 1×
“Of note, it has been previously reported that PUMA accounts for most of the p53-dependent apoptosis in the HCT116 colon carcinoma cells employed in this study (Yu et al., 2001, 2003).”
BackgroundA phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Aghajanian, C. A., Soignet, S. L., Dizon, D. S., Pien, C. S., Adams, J., Elliott, P. J., Sabbatini, P. J., Miller, V. A., Hensley, M. L., Pezzulli, S., et al. (2002) · PubMed · Cited by 447
Papandreou, C. N., Daliani, D. D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C. S., Millikan, R. E., Tu, S.-M., Pagliaro, L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.106 · Cited by 434 · cited 2×
“In recent years modulation of proteasomal function with specific inhibitors has evolved as a novel target for the treatment of cancers such as multiple myeloma (Chauhan et al., 2005) as well as lung, colon and prostate cancer (Aghajanian et al., 2002; Papandreou et al., 2004; Chauhan et al., 2005).”
BackgroundHan, J.-W., Flemington, C., Houghton, A. B., Gu, Z., Zambetti, G. P., Lutz, R. J., Zhu, L., & Chittenden, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201208798 · Cited by 427 · cited 6×
“In order to investigate whether p53 was required for PUMA induction following proteasomal stress we utilized luciferase reporter assays employing a WT and a mutant PUMA promoter, where the p53 binding site is disrupted by point mutations (Han et al., 2001).”
BackgroundMethodInfluentialGene expression during ER stress–induced apoptosis in neurons
Reimertz, C., Kögel, D., Rami, A., Chittenden, T., & Prehn, J. H. M. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305149 · Cited by 367
Self-citationHuang, H.-K., Joazeiro, C. A. P., Bonfoco, E., Kamada, S., Leverson, J. D., & Hunter, T. (2000) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)61427-4 · Cited by 356
Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells
Qin, J.-Z., Ziffra, J., Stennett, L., Bodner, B., Bonish, B. K., Chaturvedi, V., Bennett, F., Pollock, P. M., Trent, J. M., Hendrix, M. J. C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0676 · Cited by 336 · cited 2×
“, 2000), as well as melanoma and myeloma cells (Qin et al., 2005).”
BackgroundHuang, H.-K., Joazeiro, C. A. P., Bonfoco, E., et al. (2000) · PubMed · doi:10.1074/jbc.c000199200 · Cited by 333 · cited 1×
“An endogenous caspase inhibitor family of proteins, the inhibitor of apoptosis (IAPs), not only inhibit active caspases but also target them for destruction by acting as ubiquitin ligases and promoting polyubiquitination of activate caspases (Huang et al., 2000; Suzuki et al., 2001).”
BackgroundMeiners, S., Heyken, D., Weller, A., Ludwig, A., Stangl, K., Kloetzel, P.-M., & Krüger, E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301032200 · Cited by 318 · cited 1×
“Indeed, previous studies have demonstrated transcriptional induction of proteasomal subunits following proteasomal inhibition (Meiners et al., 2003).”
BackgroundKey roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy
Tan, T.-T., Degenhardt, K., Nelson, D. A., Beaudoin, B., Nieves-Neira, W., Bouillet, P., Villunger, A., Adams, J. M., & White, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.008 · Cited by 284 · cited 1×
“However, it remains plausible that increased expression of Bim in response to PIs may be of therapeutic benefit when used in combination with other agents such as TRAIL and paclitaxel (Nikrad et al., 2005; Tan et al., 2005).”
BackgroundSelf-citationAccumulation of p53 in a mutant cell line defective in the ubiquitin pathway.
Chowdary, D. R., Dermody, J. J., Jha, K. K., & Ozer, H. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1997 · Cited by 278 · cited 1×
“Indeed, the activity of several transcription factors, including p53 and nuclear factor kappa B (NF-kB) (Chowdary et al., 1994; Palombella et al., 1994), are known to be modulated by proteasome activity.”
BackgroundApoptosis induction resulting from proteasome inhibition
SHINOHARA, K., TOMIOKA, M., NAKANO, H., TONÉ, S., ITO, H., & KAWASHIMA, S. (1996) · Biochemical Journal · doi:10.1042/bj3170385 · Cited by 244 · cited 2×
“…glioma cells (Wagenknecht et al., 1999; Yin et al., 2005), the majority of reports suggest that PIs induce a p53-dependent form of apoptosis in most cancer cell types, such as leukemia cells (Shinohara et al., 1996; Masdehors et al., 2000), as well as melanoma and myeloma cells (Qin et al., 2005).”
BackgroundYin, D., Zhou, H., Kumagai, T., Liu, G., Ong, J. M., Black, K. L., & Koeffler, H. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208225 · Cited by 232 · cited 1×
“Although PIs have been shown to induce p53-independent apoptosis in glioma cells (Wagenknecht et al., 1999; Yin et al., 2005), the majority of reports suggest that PIs induce a p53-dependent form of apoptosis in most cancer cell types, such as leukemia cells (Shinohara et al., 1996; Masdehors et…”
BackgroundActivating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination
Yan, C., Lu, D., Hai, T., & Boyd, D. D. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600712 · Cited by 214 · cited 1×
“Interestingly, ATF3, a recently identified positive regulator of p53 stability (Yan et al., 2005), was also found to be transcriptionally induced and may represent a positive feed back loop further amplifying p53 activation during proteasomal stress.”
BackgroundEpoxomicin, a new antitumor agent of microbial origin.
HANADA, M., SUGAWARA, K., KANETA, K., TODA, S., NISHIYAMA, Y., TOMITA, K., YAMAMOTO, H., KONISHI, M., & OKI, T. (1992) · The Journal of Antibiotics · doi:10.7164/antibiotics.45.1746 · Cited by 213 · cited 2×
“…1681–1692 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc hydrolytic-like activities of the proteasome (Meng et al., 1999), and was first identified and isolated from a species of actinomycetes on the basis of its antitumor activity (Hanada et al., 1992).”
BackgroundInfluentialUbiquitin-mediated Degradation of the Proapoptotic Active Form of Bid
Breitschopf, K., Zeiher, A. M., & Dimmeler, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001083200 · Cited by 199 · cited 2×
“The proapoptotic Bcl-2 family proteins Bim, Bik and Bid, which regulate the release of proapoptotic factors such as cytochrome c and Smac from mitochondria, are known substrates for targeted ubiquitination and degradation (”
BackgroundNikrad, M., Johnson, T., Puthalalath, H., Coultas, L., Adams, J., & Kraft, A. S. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0260 · Cited by 180 · cited 2×
“Consistent with previous reports we found increased expression of Bim following inhibition of the proteasome (Nikrad et al., 2005), however, our data argues against a significant role of Bim in our model.”
BackgroundResultGanten, T. M., Koschny, R., Haas, T. L., Sykora, J., Li-Weber, M., Herzer, K., & Walczak, H. (2005) · Hepatology · doi:10.1002/hep.20807 · Cited by 170 · cited 1×
“Despite these observations, inhibition of NF-kB is not required to sensitize hepatocellular carcinoma cells, keratinocytes and lymphoma cells to apoptosis (Kurland and Meyn, 2001; Leverkus et al., 2003; Ganten et al., 2005).”
BackgroundVillunger, A., Scott, C., Bouillet, P., & Strasser, A. (2003) · Blood · doi:10.1182/blood-2002-07-2132 · Cited by 155 · cited 3×
“Oncogene imbalance between proapoptotic and antiapoptotic Bcl-2 proteins resulting in the release of cytochrome c and apoptosis (Villunger et al., 2003a; Willis and Adams, 2005).”
BackgroundMethodSelf-citationAugmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition
Amiri, K. I., Horton, L. W., LaFleur, B. J., Sosman, J. A., & Richmond, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0673 · Cited by 155 · cited 1×
“Indeed, inactivation of NF-kB has been suggested to play a major role in the antitumor effect of the PI, Bortezomib (Velcade/PS-341), in multiple myeloma (Hideshima et al., 2002) and melanoma cells (Amiri et al., 2004).”
BackgroundProteasome inhibitors as new anticancer drugs
Adams, J. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200211000-00007 · Cited by 141 · cited 1×
“Proteasome inhibitors (PIs) have been demonstrated to overcome chemoresistance of tumor cells by enhancing chemosensitivity and even acting in synergy with other agents to induce apoptotic cell death of tumor cells (Adams, 2002; Park and Lenz, 2004).”
BackgroundPROTEASOME INHIBITION IN MULTIPLE MYELOMA: Therapeutic Implication
Chauhan, D., Hideshima, T., & Anderson, K. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100037 · Cited by 136 · cited 3×
“In recent years modulation of proteasomal function with specific inhibitors has evolved as a novel target for the treatment of cancers such as multiple myeloma (Chauhan et al., 2005) as well as lung, colon and prostate cancer (Aghajanian et al.”
BackgroundProteasome inhibition induces hepatic stellate cell apoptosis
Anan, A., Baskin-Bey, E. S., Bronk, S. F., Werneburg, N. W., Shah, V. H., & Gores, G. J. (2006) · Hepatology · doi:10.1002/hep.21036 · Cited by 131 · cited 1×
“Interestingly, in agreement with our findings a recent study demonstrated increased Bim expression following proteasome inhibition, although siRNA-mediated knockdown of Bim afforded no protection (Anan et al., 2006).”
ResultLeverkus, M., Sprick, M. R., Wachter, T., Mengling, T., Baumann, B., Serfling, E., Brücker, E.-B., Goebeler, M., Neumann, M., & Walczak, H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.3.777-790.2003 · Cited by 128 · cited 1×
“Despite these observations, inhibition of NF-kB is not required to sensitize hepatocellular carcinoma cells, keratinocytes and lymphoma cells to apoptosis (Kurland and Meyn, 2001; Leverkus et al., 2003; Ganten et al., 2005).”
BackgroundMarshansky, V., Wang, X., Bertrand, R., Luo, H., Duguid, W., Chinnadurai, G., Kanaan, N., Vu, M. D., & Wu, J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3130 · Cited by 119 · cited 1×
“The proapoptotic Bcl-2 family proteins Bim, Bik and Bid, which regulate the release of proapoptotic factors such as cytochrome c and Smac from mitochondria, are known substrates for targeted ubiquitination and degradation (Breitschopf et al., 2000; Marshansky et al., 2001; Ley et al., 2003).”
BackgroundMasdehors, P., Merle‐Béral, H., Maloum, K., Ōmura, S., Magdelénat, H., & Delić, J. (2000) · Blood · doi:10.1182/blood.v96.1.269 · Cited by 109 · cited 2×
“…glioma cells (Wagenknecht et al., 1999; Yin et al., 2005), the majority of reports suggest that PIs induce a p53-dependent form of apoptosis in most cancer cell types, such as leukemia cells (Shinohara et al., 1996; Masdehors et al., 2000), as well as melanoma and myeloma cells (Qin et al., 2005).”
BackgroundWagenknecht, B., Hermisson, M., Groscurth, P., Liston, P., Krammer, P. H., & Weller, M. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752288.x · Cited by 92 · cited 1×
“Because of the evidence of cytochrome c release in our model and in previous studies employing PIs (”
ResultPuma and p53 Play Required Roles in Death Evoked in a Cellular Model of Parkinson Disease
Biswas, S. C., Ryu, E. J., Park, C., Malagelada, C., & Greene, L. A. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6877-5 · Cited by 80 · cited 3×
“Interestingly, several recent studies have also demonstrated a concomitant induction of Bim and PUMA following treatment with the oxidative stress-inducing agents 6-OHDA (Biswas et al., 2005) and arsenite (Wong et al.”
BackgroundWong, H. K., Fricker, M., Wyttenbach, A., Villunger, A., Michalak, E. M., Strasser, A., & Tolkovsky, A. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.19.8732-8747.2005 · Cited by 80 · cited 2×
“In both scenarios the inhibition of PUMA expression was found to be sufficient to dramatically reduce the extent of apoptosis, whereas loss of Bim expression incurred no advantage with equivalent levels of cell death seen in WT and Bim / cells (Biswas et al., 2005; Wong et al., 2005).”
BackgroundSelf-citationProteasome Inhibitors Induce p53/p21-Independent Apoptosis in Human Glioma Cells
Wagenknecht, B., Hermisson, M., Eitel, K., & Weller, M. (1999) · Cellular Physiology and Biochemistry · doi:10.1159/000016308 · Cited by 66 · cited 2×
“Although PIs have been shown to induce p53-independent apoptosis in glioma cells (Wagenknecht et al., 1999; Yin et al., 2005), the majority of reports suggest that PIs induce a p53-dependent form of apoptosis in most cancer cell types, such as leukemia cells (Shinohara et al., 1996; Masdehors et…”
BackgroundReimertz, C., Kögel, D., Lankiewicz, S., Poppe, M., & Prehn, J. H. M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00503.x · Cited by 64 · cited 2×
“Sodium dodecylsulfate–polyacrylamide gel electrophoresis and Western blotting Preparation of cell lysates and Western blotting was carried out as described (”
MethodSelf-citationCeballos, E., Muñoz-Alonso, M. J., Berwanger, B., Acosta, J. C., Hernández, R., Krause, M., Hartmann, O., Eilers, M., & León, J. (2005) · Oncogene · doi:10.1038/sj.onc.1208652 · Cited by 54 · cited 1×
“Furthermore, c-myc has been shown to have an inhibitory effect on p53-dependent target gene expression and apoptosis (Ceballos et al., 2005).”
BackgroundEffect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons
Kikuchi, S., Shinpo, K., Tsuji, S., Takeuchi, M., Yamagishi, S.-I., Makita, Z., Niino, M., Yabe, I., & Tashiro, K. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04030-1 · Cited by 51 · cited 1×
“Consistent with previously published data that suggest proteasomal stress is associated with increases in the production of reactive oxygen species (Kikuchi et al., 2003), is the transcriptional activation of several genes involved in the defence against oxidative stress.”
BackgroundProtease inhibitors restore radiation‐induced apoptosis to Bcl‐2‐expressing lymphoma cells
Kurland, J. F., & Meyn, R. E. (2001) · International Journal of Cancer · doi:10.1002/ijc.1040 · Cited by 46 · cited 2×
“Despite these observations, inhibition of NF-kB is not required to sensitize hepatocellular carcinoma cells, keratinocytes and lymphoma cells to apoptosis (Kurland and Meyn, 2001; Leverkus et al., 2003; Ganten et al., 2005).”
BackgroundDiscovery of the ubiquitin proteasome system and its involvement in apoptosis
Editors, O. B. O. T., & Melino, G. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401740 · Cited by 39 · cited 1×
“Inhibitors with a broader specificity and irreversible binding have likewise been identified and are currently being tested in preclinical trials (Melino, 2005).”
BackgroundThe role of proteasome inhibitors in solid tumors
Park, D. S., & Lenz, H. (2004) · Annals of Medicine · doi:10.1080/07853890410029031 · Cited by 33 · cited 1×
“Proteasome inhibitors (PIs) have been demonstrated to overcome chemoresistance of tumor cells by enhancing chemosensitivity and even acting in synergy with other agents to induce apoptotic cell death of tumor cells (Adams, 2002; Park and Lenz, 2004).”
Background
Research works printed but not linked: 1
- Adams J . (2004b). The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349–360. · DOI · Paper page
Cited by
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,176
“In tumor cells with wild-type p53, however, proteasome inhibitors can instead act by driving p53-dependent expression of Puma (Concannon et al., 2006).”
BackgroundPUMA, a potent killer with or without p53
Yu, J., & Zhang, L. (2008) · Oncogene · doi:10.1038/onc.2009.45 · Cited by 554
“, 2005), and cancer cell death induced by the proteasome inhibitors MG-132, bortezomib and epoxomicin (Concannon et al., 2007; Ding et al., 2007), and by the monoflavonoid wogonin (Lee et al.”
An Epstein-Barr virus–encoded microRNA targets PUMA to promote host cell survival
Choy, E. Y.-W., Siu, K.-L., Kok, K.-H., Lung, R. W.-M., Tsang, C. M., To, K.-F., Kwong, D. L.-W., Tsao, S. W., & Jin, D.-Y. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072581 · Cited by 462
Bcl-2 family on guard at the ER
Szegezdi, E., MacDonald, D. C., Ní Chonghaile, T., Gupta, S., & Samali, A. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00612.2008 · Cited by 241
“Puma has also been shown to be required for the initiation of apoptosis in neuronal cells triggered by the abnormal accumulation of malformed proteins associated with several neurodegenerative diseases (for example, amyotrophic lateral sclerosis; 54) or as a result of disrupting cellular protein degradation pathways u…”
BackgroundDayal, S., Sparks, A., Jacob, J., Allende-Vega, N., Lane, D. P., & Saville, M. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805871200 · Cited by 199
Metadata
- Authors
- Concannon, C. G., Koehler, B. F., Reimertz, C., Murphy, B. M., Bonner, C., Thurow, N., Ward, M. W., Villunger, A., Strasser, A., Kögel, D., & Prehn, J. H. M.
- Affiliations
- Royal College of Surgeons in Ireland (IE)
- Goethe University Frankfurt (DE)
- Innsbruck Medical University (AT)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Prehn, J H M
- Venue
- Oncogene
- Published
- 2006-09-18
- Volume
- 26
- Issue
- 12
- Pages
- 1681-1692
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2056205420
- Cited by
- 95
- References
- 55
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 7 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 2 · 2014: 6 · 2013: 4 · 2012: 6
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Science Foundation Ireland
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- proteasome inhibition, apoptosis, p53, PUMA, building information modeling, BH3-only proteins, epoxomicin, caspase activation, cytochrome c release, neuroblastoma, colon cancer, transcriptional regulation, antineoplastic therapy, p53-dependent apoptosis
- MeSH terms
- Base Sequence, Humans, Molecular Sequence Data, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Apoptosis, Protein Folding, DNA Primers, Oligonucleotide Array Sequence Analysis, Cell Line, Tumor, Apoptosis Regulatory Proteins, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.